Back to Atlas
APotentially durableResearch-only / high verification need
CMP-0010
Research tool
ABT-737
Senolytic / BCL-2 family
Preclinical senescent-cell apoptosis induction
Reading this compound Reference only
Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.
Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.
Mechanism & Use
- Compound type
- Small molecule
- Primary mechanism
- BCL-2/BCL-xL/BCL-w inhibition
- Primary market use
- Senolytic research
Pharmacology
- Molecular weight (Da)
- 813.43
- Oral bioavailability
- N/A; not orally bioavailable
- Half-life
- ~18 hours
- Route tags
- Oral
- Evidence level
- Preclinical
- Clinical status
- Research tool
- Value-for-money score
- 2 / 10
Reported protocol signal
No popular protocol verified yet; keep as reference compound until protocol signal is added.
For orientation only. See disclaimer — always consult a licensed clinician before use.
Notes
Predecessor to navitoclax; limited practical value due poor oral bioavailability